Ironwood Pharma (IRWD) Misses Q1 EPS by 12c, Sales Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Remains Bullish on Ironwood Pharma (IRWD) Following 1Q
May 8, 2017 4:24 PM EDTCowen reiterated an Outperform rating and $20.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's 1Q earnings report. IRWD reported US net sales of $147.6M in 1Q17 which was below the consensus estimates of $172.8M. The miss was driven by seasonality and differences in... More
